This drug is a small molecule inhibitor of Target X, a novel target proposed by Insilico Medicine’s AI target discovery engine platform PandaOmics for fibrotic diseases. The drug demonstrated robust in vitro and in vivo efficacy in inhibiting inflammation, myofibroblast activation, and fibrotic-related tissue remodeling. Its use could potentially treat idiopathic pulmonary fibrosis and kidney fibrosis.
×
Insilico Medicine � Target X Inhibitor (Fibrotic diseases treatment)
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.
Powered by MMD